Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8371655 | 0.83 | CYP2D6 (0.35) | KDM4EPOLBKMT2ATDP1 | |
| SCHEMBL8374847 | 0.76 | — | — | |
| SCHEMBL7819308 | 0.69 | KDM4E (0.36) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL14510749 | 0.67 | KDM4E (0.37) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL938191 | 0.66 | KMT2A (0.39) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL11227178 | 0.65 | KDM4E (0.44) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL6070489 | 0.61 | KMT2A (0.44) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL17234253 | 0.60 | CYP2D6 (0.44) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL7504798 | 0.60 | KMT2A (0.51) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL11226068 | 0.60 | KDM4E (0.40) | KDM4EMEN1POLBMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434753-B2 | Modified creatine compounds | GENCIA CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150005258-A1 | Modified Creatine Compounds | Genci Corporation (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140045798-A1 | MITOCHONDRIAL COMPOSITIONS AND USES THEREOF | GENCIA CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2013043580-A2 | MODIFIED CREATINE COMPOUNDS | GENCIA CORPORATION (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20130072462-A1 | Mitochondrial Compositions and Uses Thereof | GENCIA CORPORATION (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120141391-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110085993-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110021632-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110008272-A1 | Use of Creatine or Creatine Compounds for Skin Preservation | AVICENA GROUP, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100329997-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100303840-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENA GROUP, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100226870-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100179106-A1 | MITOCHONDRIAL COMPOSITIONS AND USES THEREOF | GENCIA CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20090298943-A1 | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disorders | AVICENA GROUP, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20080119450-A1 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | AVICENA GROUP, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20070253944-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-7285573-B2 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | AVICENA GROUP, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7186754-B2 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-6706764-B2 | TREATMENT OF DIABETIC AND TOXIC NEUROPATHIES, PERIPHERAL NERVOUS SYSTEM DISEASES, ALZHEIMER DISEASE, PARKINSON'S DISEASE, STROKE, HUNTINGTON'S DISEASE, AMYOTROPIC LATERAL SCLEROSIS | AVICENA GROUP, INC. | 2004-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045798-A1 | MITOCHONDRIAL COMPOSITIONS AND USES THEREOF | CS, UQCRC1, UQCRC2 | KDM4E 3876/4885MEN1 800/4885POLB 714/4885 |
| US-20110008272-A1 | Use of Creatine or Creatine Compounds for Skin Preservation | PC, CKMT1A; CKMT1B, CHEK1 | KDM4E 1339/4885MEN1 3935/4885POLB 352/4885 |
| US-20120141391-A1 | Use of creatine or creatine compounds for skin preservation | PC, CKMT1A; CKMT1B, CHEK1 | KDM4E 1339/4885MEN1 3935/4885POLB 352/4885 |
| US-20100329997-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | KDM4E 1339/4885MEN1 3935/4885POLB 352/4885 |
| US-20100303840-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | CKMT1A; CKMT1B, PC, PCK2 | KDM4E 3280/4885MEN1 4080/4885POLB 611/4885 |
| US-20110021632-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | KDM4E 1339/4885MEN1 3935/4885POLB 352/4885 |
| US-20100226870-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | KDM4E 1339/4885MEN1 3935/4885POLB 352/4885 |
| US-20070253944-A1 | Use of creatine or creatine compounds for skin preservation | PC, CKMT1A; CKMT1B, CHEK1 | KDM4E 1339/4885MEN1 3935/4885POLB 352/4885 |
| US-20090298943-A1 | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disorders | CKMT1A; CKMT1B, PCK1, TKT | KDM4E 1038/4885MEN1 4302/4885POLB 2134/4885 |
| US-20110085993-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | KDM4E 1339/4885MEN1 3935/4885POLB 352/4885 |
| US-20130072462-A1 | Mitochondrial Compositions and Uses Thereof | UQCRC1, CS, UQCRC2 | KDM4E 3692/4885MEN1 1039/4885POLB 602/4885 |
| US-20100179106-A1 | MITOCHONDRIAL COMPOSITIONS AND USES THEREOF | PC, CKMT1A; CKMT1B, SLC25A1 | KDM4E 3841/4885MEN1 594/4885POLB 973/4885 |
| US-20150005258-A1 | Modified Creatine Compounds | CKMT1A; CKMT1B, SLC25A20, ARG2 | KDM4E 1279/4885MEN1 4191/4885POLB 1245/4885 |
| US-20080119450-A1 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | CKMT1A; CKMT1B, PC, PCK2 | KDM4E 3280/4885MEN1 4080/4885POLB 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.